Anticonvulsant Efficacy in Sturge-Weber Syndrome

Emma H. Kaplan, Eric H. Kossoff, Catherine D. Bachur, Milton Gholston, Jihoon Hahn, Matthew Widlus, Anne M. Comi

Research output: Research - peer-reviewArticle

Abstract

Objective: We analyzed individuals with epilepsy due to Sturge-Weber syndrome to determine which anticonvulsants provided optimal seizure control and which resulted in the fewest side effects. Methods: One-hundred-eight records from a single center were retrospectively analyzed for Sturge-Weber syndrome brain involvement, epilepsy, Sturge-Weber syndrome neuroscores, and currently used anticonvulsants. Results: Of the fourteen anticonvulsants that had been employed, the most often used agents were oxcarbazepine or carbamazepine, and levetiracetam. Individuals whose seizures at the most recent visit were fully controlled (seizure-free) for 6 months or longer were more likely to have ever tried, or currently used, oxcarbazepine or carbamazepine than those with uncontrolled seizures. Thirty-nine of 69 individuals (56.5%) were seizure-free with oxcarbazepine or carbamazepine history versus 11 of 35 individuals (31.4%) who had not taken these agents (P <0.05); 38 of 62 patients (61.3%) were seizure-free while currently taking these anticonvulsants versus 12 of 42 (28.6%) not taking them (P <0.01). Patients with seizure control for 6 months or longer were less likely to have ever tried, or to currently be taking, levetiracetam than those without control. Sixteen of 56 individuals (28.6%) were seizure-free with levetiracetam history versus 34 of 48 (70.8%) without it (P <0.001); 14 of 43 individuals (32.6%) were seizure-free and currently taking levetiracetam versus 36 of 61 (59.0%) not taking it (P <0.01). When topiramate was added as second-line medication, five of nine patients (55.6%) experienced decreased seizure severity, and worsening of glaucoma was not reported. Conclusions: Carbamazepine and oxcarbazepine were associated with better seizure control than levetiracetam in this Sturge-Weber syndrome cohort and so may be preferred as the initial therapy. When used as adjunctive therapy, topiramate was effective in this limited analysis without a clear increased incidence of glaucoma.

LanguageEnglish (US)
JournalPediatric Neurology
DOIs
StateAccepted/In press - Oct 30 2015

Fingerprint

Sturge-Weber Syndrome
Anticonvulsants
Seizures
etiracetam
Carbamazepine
oxcarbazepine
Glaucoma
Epilepsy
History
Therapeutics
topiramate
Incidence
Brain

Keywords

  • Anticonvulsant
  • Carbamazepine
  • Epilepsy
  • Levetiracetam
  • Oxcarbazepine
  • Side effects
  • Sturge-Weber syndrome

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Anticonvulsant Efficacy in Sturge-Weber Syndrome. / Kaplan, Emma H.; Kossoff, Eric H.; Bachur, Catherine D.; Gholston, Milton; Hahn, Jihoon; Widlus, Matthew; Comi, Anne M.

In: Pediatric Neurology, 30.10.2015.

Research output: Research - peer-reviewArticle

Kaplan EH, Kossoff EH, Bachur CD, Gholston M, Hahn J, Widlus M et al. Anticonvulsant Efficacy in Sturge-Weber Syndrome. Pediatric Neurology. 2015 Oct 30. Available from, DOI: 10.1016/j.pediatrneurol.2015.10.015
Kaplan, Emma H. ; Kossoff, Eric H. ; Bachur, Catherine D. ; Gholston, Milton ; Hahn, Jihoon ; Widlus, Matthew ; Comi, Anne M./ Anticonvulsant Efficacy in Sturge-Weber Syndrome. In: Pediatric Neurology. 2015
@article{15d44b7da0e74008af11a83072d38871,
title = "Anticonvulsant Efficacy in Sturge-Weber Syndrome",
abstract = "Objective: We analyzed individuals with epilepsy due to Sturge-Weber syndrome to determine which anticonvulsants provided optimal seizure control and which resulted in the fewest side effects. Methods: One-hundred-eight records from a single center were retrospectively analyzed for Sturge-Weber syndrome brain involvement, epilepsy, Sturge-Weber syndrome neuroscores, and currently used anticonvulsants. Results: Of the fourteen anticonvulsants that had been employed, the most often used agents were oxcarbazepine or carbamazepine, and levetiracetam. Individuals whose seizures at the most recent visit were fully controlled (seizure-free) for 6 months or longer were more likely to have ever tried, or currently used, oxcarbazepine or carbamazepine than those with uncontrolled seizures. Thirty-nine of 69 individuals (56.5%) were seizure-free with oxcarbazepine or carbamazepine history versus 11 of 35 individuals (31.4%) who had not taken these agents (P <0.05); 38 of 62 patients (61.3%) were seizure-free while currently taking these anticonvulsants versus 12 of 42 (28.6%) not taking them (P <0.01). Patients with seizure control for 6 months or longer were less likely to have ever tried, or to currently be taking, levetiracetam than those without control. Sixteen of 56 individuals (28.6%) were seizure-free with levetiracetam history versus 34 of 48 (70.8%) without it (P <0.001); 14 of 43 individuals (32.6%) were seizure-free and currently taking levetiracetam versus 36 of 61 (59.0%) not taking it (P <0.01). When topiramate was added as second-line medication, five of nine patients (55.6%) experienced decreased seizure severity, and worsening of glaucoma was not reported. Conclusions: Carbamazepine and oxcarbazepine were associated with better seizure control than levetiracetam in this Sturge-Weber syndrome cohort and so may be preferred as the initial therapy. When used as adjunctive therapy, topiramate was effective in this limited analysis without a clear increased incidence of glaucoma.",
keywords = "Anticonvulsant, Carbamazepine, Epilepsy, Levetiracetam, Oxcarbazepine, Side effects, Sturge-Weber syndrome",
author = "Kaplan, {Emma H.} and Kossoff, {Eric H.} and Bachur, {Catherine D.} and Milton Gholston and Jihoon Hahn and Matthew Widlus and Comi, {Anne M.}",
year = "2015",
month = "10",
doi = "10.1016/j.pediatrneurol.2015.10.015",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Anticonvulsant Efficacy in Sturge-Weber Syndrome

AU - Kaplan,Emma H.

AU - Kossoff,Eric H.

AU - Bachur,Catherine D.

AU - Gholston,Milton

AU - Hahn,Jihoon

AU - Widlus,Matthew

AU - Comi,Anne M.

PY - 2015/10/30

Y1 - 2015/10/30

N2 - Objective: We analyzed individuals with epilepsy due to Sturge-Weber syndrome to determine which anticonvulsants provided optimal seizure control and which resulted in the fewest side effects. Methods: One-hundred-eight records from a single center were retrospectively analyzed for Sturge-Weber syndrome brain involvement, epilepsy, Sturge-Weber syndrome neuroscores, and currently used anticonvulsants. Results: Of the fourteen anticonvulsants that had been employed, the most often used agents were oxcarbazepine or carbamazepine, and levetiracetam. Individuals whose seizures at the most recent visit were fully controlled (seizure-free) for 6 months or longer were more likely to have ever tried, or currently used, oxcarbazepine or carbamazepine than those with uncontrolled seizures. Thirty-nine of 69 individuals (56.5%) were seizure-free with oxcarbazepine or carbamazepine history versus 11 of 35 individuals (31.4%) who had not taken these agents (P <0.05); 38 of 62 patients (61.3%) were seizure-free while currently taking these anticonvulsants versus 12 of 42 (28.6%) not taking them (P <0.01). Patients with seizure control for 6 months or longer were less likely to have ever tried, or to currently be taking, levetiracetam than those without control. Sixteen of 56 individuals (28.6%) were seizure-free with levetiracetam history versus 34 of 48 (70.8%) without it (P <0.001); 14 of 43 individuals (32.6%) were seizure-free and currently taking levetiracetam versus 36 of 61 (59.0%) not taking it (P <0.01). When topiramate was added as second-line medication, five of nine patients (55.6%) experienced decreased seizure severity, and worsening of glaucoma was not reported. Conclusions: Carbamazepine and oxcarbazepine were associated with better seizure control than levetiracetam in this Sturge-Weber syndrome cohort and so may be preferred as the initial therapy. When used as adjunctive therapy, topiramate was effective in this limited analysis without a clear increased incidence of glaucoma.

AB - Objective: We analyzed individuals with epilepsy due to Sturge-Weber syndrome to determine which anticonvulsants provided optimal seizure control and which resulted in the fewest side effects. Methods: One-hundred-eight records from a single center were retrospectively analyzed for Sturge-Weber syndrome brain involvement, epilepsy, Sturge-Weber syndrome neuroscores, and currently used anticonvulsants. Results: Of the fourteen anticonvulsants that had been employed, the most often used agents were oxcarbazepine or carbamazepine, and levetiracetam. Individuals whose seizures at the most recent visit were fully controlled (seizure-free) for 6 months or longer were more likely to have ever tried, or currently used, oxcarbazepine or carbamazepine than those with uncontrolled seizures. Thirty-nine of 69 individuals (56.5%) were seizure-free with oxcarbazepine or carbamazepine history versus 11 of 35 individuals (31.4%) who had not taken these agents (P <0.05); 38 of 62 patients (61.3%) were seizure-free while currently taking these anticonvulsants versus 12 of 42 (28.6%) not taking them (P <0.01). Patients with seizure control for 6 months or longer were less likely to have ever tried, or to currently be taking, levetiracetam than those without control. Sixteen of 56 individuals (28.6%) were seizure-free with levetiracetam history versus 34 of 48 (70.8%) without it (P <0.001); 14 of 43 individuals (32.6%) were seizure-free and currently taking levetiracetam versus 36 of 61 (59.0%) not taking it (P <0.01). When topiramate was added as second-line medication, five of nine patients (55.6%) experienced decreased seizure severity, and worsening of glaucoma was not reported. Conclusions: Carbamazepine and oxcarbazepine were associated with better seizure control than levetiracetam in this Sturge-Weber syndrome cohort and so may be preferred as the initial therapy. When used as adjunctive therapy, topiramate was effective in this limited analysis without a clear increased incidence of glaucoma.

KW - Anticonvulsant

KW - Carbamazepine

KW - Epilepsy

KW - Levetiracetam

KW - Oxcarbazepine

KW - Side effects

KW - Sturge-Weber syndrome

UR - http://www.scopus.com/inward/record.url?scp=84961233833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961233833&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2015.10.015

DO - 10.1016/j.pediatrneurol.2015.10.015

M3 - Article

JO - Pediatric Neurology

T2 - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -